What factors drove the changes in Neogenomics's revenue and profit?

What is the market's earnings forecast for Neogenomics next quarter?

What does Neogenomics do and what are its main business segments?

What is Neogenomics's latest dividend and current dividend yield?

What were the key takeaways from Neogenomics's earnings call?

Did Neogenomics beat or miss consensus estimates last quarter?

What is Neogenomics's gross profit margin?

What guidance did Neogenomics's management provide for the next earnings period?

**Key Takeaways:**
- **Revenue Momentum**: 12% YoY growth driven by 24% NGS expansion and 15% clinical volume growth.
- **MRD Breakthrough**: RaDaR ST launch in Q1 2026 targets $30B MRD market, with pharma bookings starting Q4 2025.
- **Operational Efficiency**: LIMS consolidation and sales force expansion to drive 2026+ margin improvement.
- **Strategic Focus**: Community oncology consolidation (80%+ cancer care) and AI-driven MRD innovation.

**【CEO Summary Section】**
- **Revenue Growth**: Total revenue of $188 million, up 12% YoY, driven by 18% clinical revenue growth. NGS revenue grew 24% YoY, accounting for 33% of clinical revenue.
- **Strategic Initiatives**: Secured court ruling to commercialize RaDaR ST MRD assay, launching in Q1 2026. Pathline acquisition on track to accelerate Northeast growth, with integration complete.
- **Customer Experience**: Emphasized fast turnaround times (e.g., 7-day average for PanTracer LBx) and comprehensive oncology menu (over 500 tests) to consolidate community oncology send-out.
- **Guidance**: Reiterated full-year 2025 guidance: $720-726 million revenue, $41-44 million adjusted EBITDA, and $108-116 million net loss.

**【CFO Financial Commentary】**
- **Financial Highlights**: Adjusted EBITDA of $12.2 million (9th consecutive quarter of positive earnings). Operating expenses up 12% YoY due to sales team expansion and Pathline-related costs.
- **Key Metrics**: AUP increased 3% YoY (excluding Pathline), clinical test volumes up 15%. Nonclinical revenue declined 27% YoY, consistent with strategic focus on clinical growth.
- **Cash Position**: $164 million cash on hand, supporting investments in growth and operational efficiency.

**【Q&A Key Highlights】**
- **MRD Growth**: RaDaR ST expected to contribute $30 million+ in 2026, with pharma bookings starting Q4 2025. MRD market $30B+ at 30% CAGR, with Neo targeting 10%+ penetration.
- **LIMS Rollout**: LIMS consolidation to reduce costs and improve workflow efficiency, with benefits materializing in 2026-2027.
- **Sales Force Expansion**: 2025 sales team additions driving 10%+ volume growth, with further expansion planned for 2026.
- **PanTracer LBx**: Launched in Q3, early uptake strong but reimbursement-dependent, with potential 2026 revenue contribution.
- **Pharma Recovery**: Pharma business expected to remain soft in 2026, with recovery in 2027 tied to MRD adoption and new product launches.

NEO

NEO fundamentals

You can ask Aime